Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage
Abstract
BACKGROUND: For some hypertensive patients, conventional blockade of the renin-angiotensin-aldosterone system with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers does not adequately protect against target organ damage. This may be particularly true for hypertensive patients with obesity, a condition often associated with elevated aldosterone levels. METHODS: We conducted a pre-post study of fixed, low-dose spironolactone (12.5 mg/d), added to chronic ACE inhibitor-based antihypertension regimens, in obese subjects with essential hypertension and preexistent target organ damage. Outcomes of interest were changes in blood pressure (office, 24-h, and nocturnal), urinary albumin excretion, and potassium. RESULTS: 21 subjects with mean age 57.3 +/- 7.1 years, BMI 32.4 +/- 3.4 kg/m2 and 12.0 +/- 7.0 years of antihypertensive therapy were enrolled. The mean aldosterone level before spironolactone treatment was 10.1 +/- 7.3 ng/dl, and over 40% of subjects had baseline levels greater than mean population levels. During 4 weeks of low-dose spironolactone, mean office (110.6 +/- 7.8 to 105.0 +/- 8.1 mmHg, p = 0.004), 24-hour ambulatory (100.6 +/- 9.4 to 95.5 +/- 7.1 mmHg, p = 0.03) and nocturnal (95.3 +/- 11.5 to 87.5 +/- 8.2, p = 0.004) blood pressures all declined significantly. Log urine albumin : creatinine ratios also significantly dropped during spironolactone treatment (p = 0.002); in multivariate analysis, this decline did not appear to be due to changes in blood pressure but was influenced by concomitant changes in estimated glomerular filtration rate. Both the reductions in blood pressure and albumin excretion reversed after withdrawal of spironolactone. Serum potassium levels were essentially unchanged by low-dose spironolactone (p = 0.9). CONCLUSIONS: A fixed, low-dose of spironolactone, added to chronic ACE inhibitor therapy, reduced blood pressure and urinary albumin excretion in obese subjects with hypertension and preexistent target organ damage. A relative hyperaldosteronism due to aldosterone escape and/or obesity may explain the beneficial effects of spironolactone therapy in this study.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In patients with obesity and hypertension, MR antagonism with spironolactone reduced blood pressure and urinary albumin excretion even after long-term blockade of angiotensin II formation with ACE inhibitors.
“In patients with obesity and hypertension, MR antagonism with spironolactone reduced BP and urinary albumin excretion even after long-term blockade of AngII formation with ACE inhibitors72.”
From Obesity, kidney dysfunction and hypertension: mechanistic links (2019) · cites this paper as [72]
Cited by
Sorted by citations
Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis
D’Agati, V. D., Chagnac, A., de Vries, A. P. J., Levi, M., Porrini, E., Herman‐Edelstein, M., & Praga, M. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.75 · Cited by 726 · see citing works
Obesity, kidney dysfunction and hypertension: mechanistic links
Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z., & Hall, M. E. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0145-4 · Cited by 654 · see citing works
Obesity, hypertension, and chronic kidney disease
Hall, J., Juncos, L., Wang, Z., Hall, M., do Carmo, J., & da Silva, A. (2014) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s39739 · Cited by 520 · see citing works
Role of Hyperinsulinemia and Insulin Resistance in Hypertension: Metabolic Syndrome Revisited
da Silva, A. A., do Carmo, J. M., Li, X., Wang, Z., Mouton, A. J., & Hall, J. E. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.02.066 · Cited by 381 · see citing works
Obesity, kidney dysfunction, and inflammation: interactions in hypertension
Hall, J. E., Mouton, A. J., da Silva, A. A., Omoto, A. C. M., Wang, Z., Li, X., & do Carmo, J. M. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa336 · Cited by 279 · see citing works
“Also, spironolactone reduced BP and urinary albumin excretion in obese hypertensive subjects even after blockade of AngII formation.(95) Compared to other antihypertensive drugs, the MR antagonist spiro-”
BackgroundImpact of different ectopic fat depots on cardiovascular and metabolic diseases
Ferrara, D., Montecucco, F., Dallegri, F., & Carbone, F. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28821 · Cited by 195 · see citing works
Adipocytes, aldosterone and obesity-related hypertension
Cat, A. N. D., Friederich‐Persson, M., White, A. D., & Touyz, R. M. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-16-0025 · Cited by 96 · see citing works
Kidney Damage Caused by Obesity and Its Feasible Treatment Drugs
Wang, M., Wang, Z., Chen, Y., & Dong, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020747 · Cited by 79 · see citing works
New Pandemic: Obesity and Associated Nephropathy
Sharma, I., Liao, Y., Zheng, X., & Kanwar, Y. S. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.673556 · Cited by 57 · see citing works
Ross, E. L., Heizer, J. W., Mixon, M. A., Jorgensen, J. E., Valdez, C. A., Czaja, A. S., & Reiter, P. D. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140280 · Cited by 54 · see citing works
Bomback, A. S., Rekhtman, Y., Klemmer, P. J., Canetta, P. A., Radhakrishnan, J., & Appel, G. B. (2012) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2012.07.003 · Cited by 46 · see citing works
Self-citationCox, J. M., Chu, H. D., Yang, C., Shen, H. C., Wu, Z., Balsells, J., Crespo, A., Brown, P. N., Zamlynny, B., Wiltsie, J., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.02.057 · Cited by 26 · see citing works
Özbek, L., Abdel‐Rahman, S. M., Unlu, S., Güldan, M., Copur, S., Burlacu, A., Covic, A. C., & Kanbay, M. (2024) · Medicina · doi:10.3390/medicina60101668 · Cited by 22 · see citing works
“Aldosterone increase is suggested to play a role in the development of resistant AH in obese individuals, as spironolactone treatment results in significantly reduced blood pressure and proteinuria in these patients [125].”
BackgroundAldosterone blockade in chronic kidney disease.
Hirsch, J. S., Drexler, Y., & Bomback, A. S. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.04.006 · Cited by 25 · see citing works
Self-citationEfficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes
Oiwa, A., Hiwatashi, D., Takeda, T., Miyamoto, T., Kawata, I., Koinuma, M., Yamazaki, M., & Komatsu, M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad144 · Cited by 22 · see citing works
Morales, E., Gutiérrez, E., Caro, J., Sevillano, Á., Rojas-Rivera, J. E., & Praga, M. (2015) · Nefrología · doi:10.1016/j.nefro.2015.09.008 · Cited by 20 · see citing works
“Tras un seguimiento de 28,9 meses (14-84), hubo una reducción del 59,4% de la proteinuria en el grupo de obesidad (2,8 ± 2,1 frente a 1,3 ± 1,6 g/24 h, p < 0,05).”
BackgroundYang, C., Shen, H. C., Wu, Z.-C., Chu, H. D., Cox, J. M., Balsells, J., Crespo, A., Brown, P., Zamlynny, B., Wiltsie, J., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.077 · Cited by 16 · see citing works
Glomerular Diseases in Diabetic Patients: Implications for Diagnosis and Management
Oliva-Dámaso, N., Mora‐Gutiérrez, J. M., & Bomback, A. S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091855 · Cited by 15 · see citing works
“A low dose of spironolactone, added to angiotensin-converting enzyme inhibitor (ACEi) therapy, reduced blood pressure and urinary albumin excretion in obese hypertensive subjects [35].”
BackgroundSelf-citationVerdonschot, J. A. J., Ferreira, J. P., Pizard, A., Pellicori, P., Rocca, H. B., Clark, A. L., Cosmi, F., Cuthbert, J. J., Girerd, N., Waring, O. J., et al. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.12.005 · Cited by 8 · see citing works
“14 However, even if the effects of spironolactone on blood pressure are greater in those with obesity, spironolactone still improved cardiac remodeling in those without obesity, suggesting additional bene fi cial mechanisms in people at risk beyond blood pressure reduction.”
BackgroundObesity-Associated Hypertension
Uwaifo, G. (2013) · Humana Press eBooks · doi:10.1007/978-1-60761-548-4_13 · Cited by 39 · see citing works
Efficacy and safety of finerenone in obesity-related glomerulopathy
Qiu, D., Liu, J., Chen, R.-H., Zhang, F., An, Y., & Jiang, S. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf157 · Cited by 6 · see citing works
Mineralocorticoid Receptor Antagonists in Essential and Resistant Hypertension
Imprialos, K. P., Bouloukou, S., Kerpiniotis, G., Katsimardou, A., Patoulias, D., Bakogiannis, C., & Faselis, C. J. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190306163310 · Cited by 6 · see citing works
Ma, J., Zhang, H., Guo, H., et al. (2014) · PubMed · Cited by 5 · see citing works
Guasti, L., Gaudio, G. V., Lupi, A., D'Avino, M., Sala, C., Mugellini, A., Vulpis, V., Felis, S., Sarzani, R., Vanasia, M., et al. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s134826 · Cited by 4 · see citing works
Gupta, H., & Bhandari, U. (2024) · Current Drug Targets · doi:10.2174/0113894501314788241008115712 · Cited by 4 · see citing works
Hage, F. G., Mansur, S. J., & Oparil, S. (2011) · Therapy · doi:10.2217/thy.11.20 · Cited by 3 · see citing works
Amini, M., Dalil, D., Yaghoubi, F., Valizadeh, Z., Tavakoli, F., & Koohpayezadeh, Z. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70058 · Cited by 3 · see citing works
ALDOSTERONE AND OBESITY: WHERE TO LOOK FOR THE KEY TO THERAPY?
Vatutin, N. T., Shevelok, A. N., & Degtiarova, G. E. (2016) · The Russian Archives of Internal Medicine · doi:10.20514/2226-6704-2016-6-4-21-29 · Cited by 3 · see citing works
“В этих работах добавление низких доз спиронолактона (12,5-25 мг/сут) приводило к существенному снижению среднего офисного, среднесуточного и среднего ночного АД [9, 23, 31].”
BackgroundManagement of Hypertension in Chronic Kidney Disease
Velasquez, M. T. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411602-3.00052-4 · Cited by 3 · see citing works
Pοlyzos, S. A., Kountouras, J., Zavos, C., & Deretzi, G. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00484.x · Cited by 1 · see citing works
Potential Therapeutic Targets of Obesity-Related Glomerulopathy
He, J., Xiao, Y., & Wang, J. (2021) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2020.0141 · Cited by 1 · see citing works
Morales, E., Gutiérrez, E., Caro, J., et al. (2015) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2015.11.007 · Cited by 1 · see citing works
Stavropoulos, K., Imprialos, K. P., Doumas, M. N., et al. (2019) · Current Pharmaceutical Design · doi:10.2174/138161282446190426120024
Hyperaldosteronismus und verstärkte Aktivität des Mineralokortikoidrezeptors
Fiebeler, A., & Quinkler, M. O. (2011) · Der Nephrologe · doi:10.1007/s11560-010-0494-2
- Authors
- Bomback, A. S., Muskala, P., Bald, E., Chwatko, G., & Nowicki, M.
- Affiliations
- Columbia University Irving Medical Center (US)
- Venue
- Clinical Nephrology
- Publisher
- Dustri-Verlag Dr. Karl Feistle
- Published
- 2009-12-01
- Volume
- 72
- Issue
- 12
- Pages
- 449-456
- ISSN
- 0301-0430 (ISSN-L)
- OpenAlex
- W2011931271
- Cited by
- 34
- References
- 0
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 4 · 2020: 2 · 2019: 4 · 2017: 1 · 2016: 3 · 2015: 3 · 2014: 5 · 2013: 1 · 2012: 2
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Nephrology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- spironolactone, ACE inhibitors, essential hypertension, obesity, hypertensive target organ damage, aldosterone, renin-angiotensin-aldosterone system, blood pressure reduction, urinary albumin excretion, albuminuria, glomerular filtration rate, serum potassium, antihypertensive therapy, nocturnal blood pressure, ambulatory blood pressure monitoring, mineralocorticoid receptor
- MeSH terms
- Albuminuria, Mineralocorticoid Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Hypertension, Male, Middle Aged, Obesity, Spironolactone, Time Factors, Treatment Outcome, Blood Pressure Monitoring, Ambulatory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
